Sentinel’s tall order
This article was originally published in The Gray Sheet
Executive Summary
FDA plans to request quotations June 1 from vendors interested in creating an active medical product surveillance system for the agency's Sentinel post-market safety initiative, FDA says in a May 15 FedBizOpps.gov notice. The selected vendor would develop a system to detect and analyze adverse event data from automated health care data systems, including electronic health records, claims databases and registries. Data should contain drug and biologic utilization, and ideally medical device utilization information, as well
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.